Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
PRODIGE 4
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
- NCT00112658 ↗
- Completed
- UNICANCER
- Standard
We haven't built an HCP commentary report on PRODIGE 4 (FOLFIRINOX in metastatic pancreatic cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PRODIGE 4 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients
- Phase
- Phase 2/Phase 3
- Status
- Completed
- Conditions
- Pancreatic Cancer
- Interventions
- fluorouracil; gemcitabine hydrochloride; irinotecan hydrochloride; leucovorin calcium; oxaliplatin
- Arms
- Folfirinox · Experimental
- Gemcitabine · Active comparator
- Enrollment
- 342
- Primary outcomes
- Objective response rate (Phase II)
- Survival (Phase III)
- Sponsor
- UNICANCER
- Start
- Nov 2004
- Primary completion
- Jun 2010
- Results posted
- No
- Registry record
- NCT00112658 · updated Mar 8, 2021
Publications
linked from the registry- Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923. PubMed 21561347
- Ychou M, Desseigne F, Guimbaud R, et al.: Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): first results of the ACCORD 11 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4516, 2007.
- Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017 Sep 20;12(9):e0183288. doi: 10.1371/journal.pone.0183288. eCollection 2017. PubMed 28931010